Link to the University of Pittsburgh Homepage
Link to the University Library System Homepage Link to the Contact Us Form

Functional analyses of ATM, ATR and Fanconi anemia proteins in lung carcinoma

Beumer, JH and Fu, KY and Anyang, BN and Siegfried, JM and Bakkenist, CJ (2015) Functional analyses of ATM, ATR and Fanconi anemia proteins in lung carcinoma. BMC Cancer, 15 (1).

[img]
Preview
PDF
Published Version
Available under License : See the attached license file.

Download (1MB) | Preview
[img] Plain Text (licence)
Available under License : See the attached license file.

Download (1kB)

Abstract

© 2015 Beumer et al. Background: ATM and ATR are kinases implicated in a myriad of DNA-damage responses. ATM kinase inhibition radiosensitizes cells and selectively kills cells with Fanconi anemia (FA) gene mutations. ATR kinase inhibition sensitizes cells to agents that induce replication stress and selectively kills cells with ATM and TP53 mutations. ATM mutations and FANCF promoter-methylation are reported in lung carcinomas. Methods: We undertook functional analyses of ATM, ATR, Chk1 and FA proteins in lung cancer cell lines. We included Calu6 that is reported to be FANCL-deficient. In addition, the cancer genome atlas (TCGA) database was interrogated for alterations in: 1) ATM, MRE11A, RAD50 and NBN; 2) ATR, ATRIP and TOPBP1; and 3) 15 FA genes. Results: No defects in ATM, ATR or Chk1 kinase activation, or FANCD2 monoubiquitination were identified in the lung cancer cell lines examined, including Calu6, and major alterations in these pathways were not identified in the TCGA database. Cell lines were radiosensitized by ATM kinase inhibitor KU60019, but no cell killing by ATM kinase inhibitor alone was observed. While no synergy between gemcitabine or carboplatin and ATR kinase inhibitor ETP-46464 was observed, synergy between gemcitabine and Chk1 kinase inhibitor UCN-01 was observed in 54T, 201T and H460, and synergy between carboplatin and Chk1 kinase inhibitor was identified in 201T and 239T. No interactions between ATM, ATR and FA activation were observed by either ATM or ATR kinase inhibition in the lung cancer cell lines. Conclusions: Analyses of ATM serine 1981 and Chk1 serine 345 phosphorylation, and FANCD2 monoubiquitination revealed that ATM and ATR kinase activation and FA pathway signaling are intact in the lung cancer cell lines examined. As such, these posttranslational modifications may have utility as biomarkers for the integrity of DNA damage signaling pathways in lung cancer. Different sensitization profiles between gemcitabine and carboplatin and ATR kinase inhibitor ETP-46464 and Chk1 kinase inhibitor UCN-01 were observed and this should be considered in the rationale for Phase I clinical trial design with ATR kinase inhibitors.


Share

Citation/Export:
Social Networking:
Share |

Details

Item Type: Article
Status: Published
Creators/Authors:
CreatorsEmailPitt UsernameORCID
Beumer, JHjhb11@pitt.eduJHB11
Fu, KY
Anyang, BN
Siegfried, JMjsiegfr@pitt.eduJSIEGFR
Bakkenist, CJcjb38@pitt.eduCJB38
Centers: Other Centers, Institutes, or Units > Hillman Cancer Center
Other Centers, Institutes, or Units > Pittsburgh Cancer Institute
Date: 5 October 2015
Date Type: Publication
Journal or Publication Title: BMC Cancer
Volume: 15
Number: 1
DOI or Unique Handle: 10.1186/s12885-015-1649-3
Schools and Programs: School of Medicine > Pharmacology and Chemical Biology
School of Medicine > Radiation Oncology
School of Pharmacy > Pharmaceutical Sciences
Refereed: Yes
Date Deposited: 05 Aug 2016 18:48
Last Modified: 05 Feb 2019 07:55
URI: http://d-scholarship.pitt.edu/id/eprint/29138

Metrics

Monthly Views for the past 3 years

Plum Analytics

Altmetric.com


Actions (login required)

View Item View Item